Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 280

1.

The term cognition-enhancing medications is misleading.

Lexchin JR.

Can Fam Physician. 2018 Nov;64(11):792. No abstract available.

2.

Cost recovery by Health Canada and drug safety: a time-series analysis.

Lexchin J.

CMAJ Open. 2018 Oct 18;6(4):E471-E477. doi: 10.9778/cmajo.20180146. Print 2018 Oct-Dec.

3.

Ten Principles for More Conservative, Care-Full Diagnosis.

Schiff GD, Martin SA, Eidelman DH, Volk LA, Ruan E, Cassel C, Galanter W, Johnson M, Jutel A, Kroenke K, Lambert BL, Lexchin J, Myers S, Miller A, Mushlin S, Sanders L, Sheikh A.

Ann Intern Med. 2018 Nov 6;169(9):643-645. doi: 10.7326/M18-1468. Epub 2018 Oct 2. No abstract available.

PMID:
30285046
4.

Canadian status of "drugs to avoid" in 2017: a descriptive analysis.

Lexchin J.

CMAJ Open. 2018 Sep 28;6(3):E430-E435. doi: 10.9778/cmajo.20180049. Print 2018 Jul-Sep.

5.
6.

Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence.

Wiktorowicz M, Moscou K, Lexchin J.

Global Health. 2018 Aug 22;14(1):86. doi: 10.1186/s12992-018-0402-5.

7.

Industry sponsorship and research outcome: systematic review with meta-analysis.

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L.

Intensive Care Med. 2018 Oct;44(10):1603-1612. doi: 10.1007/s00134-018-5293-7. Epub 2018 Aug 21. Review.

PMID:
30132025
8.

Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.

Grootendorst P, Shim M, Falconi A, Robinson T, Lexchin J.

Int J Health Serv. 2018 Oct;48(4):702-715. doi: 10.1177/0020731418789610. Epub 2018 Jul 24.

PMID:
30040005
9.

A call to mandate patient access to personal primary care medical records across Canada.

Gorfinkel I, Lexchin J.

CMAJ. 2018 Jul 23;190(29):E869-E870. doi: 10.1503/cmaj.180522. No abstract available.

PMID:
30037887
10.

Healing an ailing pharmaceutical system: prescription for reform for United States and Canada.

Gaffney A, Lexchin J; US; Canadian Pharmaceutical Policy Reform Working Group.

BMJ. 2018 May 17;361:k1039. doi: 10.1136/bmj.k1039. Review. No abstract available.

PMID:
29773533
11.

Medicines Information and the Regulation of the Promotion of Pharmaceuticals.

Leonardo Alves T, Lexchin J, Mintzes B.

Sci Eng Ethics. 2018 May 2. doi: 10.1007/s11948-018-0041-5. [Epub ahead of print]

PMID:
29721844
12.

The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries.

Gleeson D, Lexchin J, Lopert R, Kilic B.

Glob Soc Policy. 2018 Apr;18(1):7-27. doi: 10.1177/1468018117734153. Epub 2017 Oct 13.

14.

Nursing Home Physicians Discuss Caring for Elderly Residents: An Exploratory Study.

Banerjee A, James R, McGregor M, Lexchin J.

Can J Aging. 2018 Jun;37(2):133-144. doi: 10.1017/S0714980818000089. Epub 2018 Apr 5.

PMID:
29618397
15.

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis.

Lexchin J.

J Pharm Policy Pract. 2018 Mar 13;11:5. doi: 10.1186/s40545-018-0132-3. eCollection 2018.

16.

Combating corruption in the pharmaceutical arena.

Lexchin J, Kohler JC, Gagnon MA, Crombie J, Thacker P, Shnier A.

Indian J Med Ethics. 2018 Jul-Sep;3(3):234-239. doi: 10.20529/IJME.2018.022. Epub 2018 Mar 15.

17.

Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care.

Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, Beaulieu MD, Mintzes B.

Health Policy. 2018 Mar;122(3):250-255. doi: 10.1016/j.healthpol.2018.01.010. Epub 2018 Feb 1.

PMID:
29395543
18.

Composition of Canadian Pain Society guideline development group?

Lexchin JR.

Can Fam Physician. 2018 Jan;64(1):8. No abstract available.

19.

We need to mandate drug cost transparency on electronic medical records.

Gorfinkel I, Lexchin J.

CMAJ. 2017 Dec 18;189(50):E1541-E1542. doi: 10.1503/cmaj.171070. No abstract available.

PMID:
29255097
20.

Financial costs associated with monopolies on biologic medicines in Australia.

Gleeson D, Townsend B, Lopert R, Lexchin J, Moir H.

Aust Health Rev. 2017 Nov 9. doi: 10.1071/AH17031. [Epub ahead of print]

PMID:
29116927

Supplemental Content

Loading ...
Support Center